Hypereosinophilic Syndrome Has First FDA Approved Therapy in 14 Years
This week, the US FDA announced that they approved the drug Nucala (mepolizumab) to treat patients with hypereosinophilic syndrome, a rare chronic blood disease which causes organ damage. Nucala is…